March 5, 2018

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

AMENDMENTS AND UPDATES
GYNECOLOGIC
GOG-0263:Amendment 4; version date: January 23, 2018 (see  CTSU).

OTHER PROTOCOL NOTICES
1. SWOG Protocol S1613: "A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification" was activated on October 9, 2017 and is now open to patient enrollment. It is available on the CTSU menu with Dr. Marwan Fakih, a member of the NRG Oncology Colorectal Committee, as the NRG Champion. Dr. Fakih was actively involved in the development and refinement of this study and it cannot be accomplished without the NCTN given the infrequency of this patient population. We encourage our members to enroll eligible patients to this important trial. Although NRG Oncology is not the lead group on this trial, your institution can select NRG as the group credited with accrual at the time of enrollment. If NRG is selected, the enrollment will count towards membership requirements.

2. BREAST
NSABP B-39/RTOG 0413: Attention! Call for Data! (memo posted to CTSU).

NSABP B-55/BIG 6-13: Memo regarding Relocation of the SIV (posted to CTSU).

NRG-BR003:

  • NRG BR003 WebEx, Thursday March 22, 2018, at 2:00 pm ET

This WebEx is intended for PIs and research staff. The session will provide an overview of the changes in the anticipated protocol amendment and other protocol updates.  There will be time for sites to ask questions.  The session will last no more than an hour. Register to attend by sending your name, current email address, and institution name to Pam Andreyko, andreykop@nrgoncology.org. There will be no agenda or handouts for this webex. The instructions to access the WebEx will be emailed to you prior to March 22nd. Registration is limited so register by March 19th to attend.

  • Memo (one for Canadian sites and one for US sites) regarding Relocation of the SIV (posted to CTSU)

3. COLORECTAL
NRG-GI004/S1610: 

  • Bioclinica Site Manual (posted to  CTSU)
  • Memo regarding Relocation of the SIV (posted to CTSU)

4. HEAD AND NECK
NRG-HN004: The Spanish-translated consent forms are available on the CIRB documents tab of  CTSU.

5.SYMPTOM MANAGEMENT
NRG-CC004: VisionTree FAQs for participants are available on the NRG website. CIRB has approved the document. Sites not using the CIRB should submit to their local IRB prior to use.

6. VTOC TRAINING
The  VTOC Webinar Training Series schedule and registration are available for NRG Oncology Research Associates working on RTOG 0924, RTOG 0920, NRG-HN001, NRG-HN002, NRG-CC003, and NRG-CC004. Space is limited so register now and reserve your seat.  The next webinar training is scheduled for March 14, 2018.

DRUG SAFETY UPDATES
Safety updates have been issued for NSABP legacy studies. For details, please see the NSABP  E-mail Distributions page and CTSU.

Safety updates have been issued for the following NRG Oncology studies:
-Trametinib: GOG-0281

       For GOG-0281safety reports, please see CTSU.

ROSTER ROLE REMINDERS
Please note that a Site Investigator role is not required to assign investigators to enrollments in OPEN, to act as the site investigator on an IRB approval, or as the Clinical Investigator on the Delegation of Tasks Log. The assignment of Site Investigator role allows write access to Rave, and will generate automatic Rave invitations for any study on which the site participates.

PITTSBURGH SDMC SPRING HOLIDAY CLOSURE
Please note that the Pittsburgh SDMC office will be closed in observance of the University of Pittsburgh's spring holiday on Friday, March 9, 2018. All other NRG Oncology locations will be open during regular business hours on that day.

NRG Oncology is pleased to report the scientific articles and abstracts that have appeared or have been presented during the previous week. This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

JOURNAL ARTICLES

Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx162. PubMed PMID: 28954297. Read more

Rivera DR, Ganz PA, Weyrich MS, Bandos H, Melnikow J. Chemotherapy-Associated Peripheral Neuropathy in Patients With Early-Stage Breast Cancer: A Systematic Review. J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx140. Review. PubMed PMID: 28954296. Read more

Wang L, Ingle J, Weinshilboum R. Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther. 2018 Feb;103(2):243-252. doi: 10.1002/cpt.915. Epub 2017 Dec 1. PubMed PMID: 29052219; PubMed Central PMCID: PMC5760458. Read more


PUBLICATIONS REMINDERS
Please note the following upcoming meeting and abstract submission deadline dates

Upcoming Meetings
Society of Gynecologic Oncology (SGO); Mar 24-27, 2018; New Orleans, LA

Society of Surgical Oncology (SSO); Mar 21-24, 2018; Chicago, IL

St. Gallen GI Cancer Conference; Mar 15-17, 2018; St Gallen, Switzerland

United States and Canadian Academy of Pathology (USCAP); Mar 17-23, 2018; Vancouver, BC

Upcoming Abstract Submission Deadlines
American Association of Physicists in Medicine (AAPM); Jul 29 - Aug 2, 2018; Nashville, TN; meeting abstracts submission deadline Mar 8, 2018

American Society of Clinical Oncology (ASCO); Jun 1-5, 2018; Chicago, IL; Late-breaking Mar 15, 2018

American Society for Radiation Oncology (ASTRO); Oct 21-24, 2018; San Diego, CA; Late-breaking Aug 1, 2018

College of American Pathologists (CAP); Oct 20-24, Chicago, IL; meeting abstracts submission deadline Mar 9, 2018

Multinational Association of Supportive Care in Cancer (MASCC); Jun 28-30, 2018; Vienna, Austria; Late-breaking due Apr 20, 2018

 


NRG Oncology is proud to be an active participant of #CancerMoonShot.

View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address